Acthar Proposed Giveaway Program Raises Kickback Concerns, OIG Says
High price of Mallinckrodt’s H.P. Acthar Gel is important factor in conclusion, HHS Office of Inspector General advisory opinion notes.
You may also be interested in...
$15.4m fine will resolve claims of "wining and dining" doctors to get them to prescribe Acthar. Mallinckrodt dropped NORD and switched to Chronic Disease Fund to administer its copay assistance program, a move that Mallinckrodt’s COO purportedly described as "mom & pop vs. WalMart."
An advisory opinion says a program sponsored by Johnson & Johnson and AbbVie to provide up to 60 days of the cancer drug Imbruvica for free to patients who experience delays in receiving insurance coverage approval is at low risk of raising anti-kickback concerns.
US legislation attempts to address manufacturer, pharmacy benefit manager impact on patient costs in addition to health plan benefit designs. Critics suggest it’s too easy on manufacturers but that may help its chances with Republicans.